BCRX
Biocryst Pharmaceuticals Inc.
Halal Rating :
Last Price
$7.44
Last updated:
Market Cap
-
7D Change
-6.18%
1 Year Change
32.38%
Company Overview
Industries
Exchange
Next Earnings Date
BioCryst Pharmaceuticals Inc. is a biotechnology company that discovers novel, oral, small-molecule medicines. The company focuses on developing treatments for rare diseases, with its lead product ORLADEYO® (berotralstat) approved for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients. The company also has other products in its pipeline targeting rare diseases.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $117.08m | $134.22m | - | $24.83m | 0.00% | 18.50% |
| June 30, 2024 | $109.33m | $125.3m | - | $24.73m | 0.00% | 19.74% |
| March 31, 2024 | $92.76m | $131.75m | - | $24.51m | 0.00% | 18.60% |
Company Impact
Help us evaluate Biocryst Pharmaceuticals Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.